Vericel’s (VCEL) Sell (D+) Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (d+) rating on shares of Vericel (NASDAQ:VCEL) in a research report released on Friday morning,Weiss Ratings reports.

Other analysts have also recently issued reports about the company. Truist Financial decreased their price objective on Vericel from $46.00 to $41.00 and set a “buy” rating on the stock in a report on Wednesday, October 15th. Canaccord Genuity Group cut their target price on Vericel from $61.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, August 1st. BTIG Research downgraded Vericel from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 17th. Finally, Zacks Research raised Vericel from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.40.

Vericel Price Performance

Shares of VCEL opened at $36.32 on Friday. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of 302.69 and a beta of 1.39. Vericel has a 1 year low of $29.24 and a 1 year high of $63.00. The business’s 50 day simple moving average is $33.68 and its 200-day simple moving average is $38.06.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.03. The business had revenue of $63.24 million for the quarter, compared to analysts’ expectations of $64.61 million. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The company’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.10) EPS. On average, sell-side analysts expect that Vericel will post 0.14 earnings per share for the current year.

Hedge Funds Weigh In On Vericel

Hedge funds have recently bought and sold shares of the business. Ameritas Advisory Services LLC bought a new position in Vericel in the 2nd quarter valued at $30,000. CWM LLC grew its position in Vericel by 101.3% in the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 694 shares during the last quarter. AlphaQuest LLC bought a new position in Vericel in the 2nd quarter valued at $60,000. GAMMA Investing LLC grew its position in Vericel by 34.8% in the 1st quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company’s stock valued at $129,000 after acquiring an additional 748 shares during the last quarter. Finally, Osaic Holdings Inc. grew its position in Vericel by 13.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock valued at $125,000 after acquiring an additional 353 shares during the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.